Compare Harley-Davidson Inc (HOG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Moderna, Inc. — how do they compare? Harley-Davidson Inc trades at $27.75 (market cap $2.93B), while Moderna, Inc. trades at $60.04 (market cap $23.60B). The key difference: Moderna, Inc. is far larger — about 8.1× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.64% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| HOG | MRNA | |
|---|---|---|
Market Cap | $2.93B | $23.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $81.80 |
52-Week Low | $17.19 | $22.36 |
Enterprise Value | $3.32B | $19.70B |
Dividend Yield | 2.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $27.85, up 4.78% today, with a bullish technical signal from moving averages and a neutral RSI near 69. Recent earnings show mixed results, with Q1 2026 missing estimates, while revenue has declined from $5.8B in 2022 to $4.5B in 2025. The company is executing a turnaround strategy, including cost cuts and bringing Revolution Max engine production back to the U.S., amid positive retail sales growth in Q1 2026.
The outlook is cautious; while valuation ratios like P/E of 13.77 and P/B of 0.91 appear attractive, declining revenue and net income margins pose risks. Analyst consensus is mostly Hold (65.71%), with a price target of $23.40 below the current price, indicating skepticism about near-term growth despite operational initiatives.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
